Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer
暂无分享,去创建一个
Alain Friboulet | Jagadeesh Bayry | S. Kaveri | M. Kazatchkine | J. Bayry | A. Friboulet | Sriramulu Elluru | Srini V Kaveri | J. D. van Huyen | S. Delignat | Sri Ramulu Elluru | Jean-Paul Duong van Huyen | Sandrine Delignat | Michel D Kazatchkine | S. Elluru
[1] A. Büssing,et al. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. , 1999, Anticancer research.
[2] R. Steinman,et al. Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells , 1998, The Journal of experimental medicine.
[3] A. Büssing,et al. Intracellular expression of IL-4 and inhibition of IFN-gamma by extracts from European mistletoe is related to induction of apoptosis. , 2000, Anticancer research.
[4] S. Kaveri,et al. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. , 2006, Cancer letters.
[5] H. Franz,et al. Isolation and properties of three lectins from mistletoe (Viscum album L.). , 1981, The Biochemical journal.
[6] F. Stirpe,et al. Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). , 1982, The Journal of biological chemistry.
[7] P. Giacomini,et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[8] R. Herrmann,et al. A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. , 1995, Natural immunity.
[9] A. Büssing,et al. Expression of interleukin-4 in apoptotic cells: stimulation of the type-2 cytokine by different toxins in human peripheral blood mononuclear and tumor cells. , 2000, Cytometry.
[10] A. Houghton,et al. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. , 1993, The Journal of clinical investigation.
[11] B. Schneider,et al. Results from a multicenter, comparative, epidemiological cohort study in Germany , 2005 .
[12] M. Baccarani,et al. Generation of Dendritic Cells from Positively Selected CD14 + Monocytes for Anti-tumor Immunotherapy , 2004, Leukemia & lymphoma.
[13] F. Sallusto,et al. Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.
[14] A. Enk,et al. Induction of tolerance by IL-10-treated dendritic cells. , 1997, Journal of immunology.
[15] C Caux,et al. Immunobiology of dendritic cells. , 2000, Annual review of immunology.
[16] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[17] S Ferrone,et al. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. , 1999, Molecular medicine today.
[18] F. Brasseur,et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.
[19] R. Steinman,et al. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. , 1999, Human immunology.
[20] A. Anichini,et al. T-cell response to unique and shared antigens and vaccination of cancer patients. , 2002, Cancer immunity.
[21] E. Jaffee,et al. Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.
[22] T. Chao,et al. Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-beta1 and interleukin-6 in the development of in situ tumor immunity. , 2005, Immunobiology.
[23] R. Wolfram,et al. Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer , 2000, International journal of cancer.
[24] A. Büssing,et al. Toxic proteins from European mistletoe (Viscum album L.): increase of intracellular IL-4 but decrease of IFN-gamma in apoptotic cells. , 2000, Anticancer research.
[25] R. Wolfram,et al. Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. , 2006, European journal of medical research.
[26] F. Jotereau,et al. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.
[27] P. Dalerba,et al. Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.
[28] T. Khwaja,et al. Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. , 1986, Oncology.
[29] S. Kaveri,et al. Molecular Mechanisms Underlying the Immunomodulatory Effects of Mistletoe (Viscum album L.) Extracts Iscador , 2006, Arzneimittelforschung.
[30] J. Beuth,et al. Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. , 2005, Anticancer research.
[31] S. Lyu,et al. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. , 2001, Cancer biotherapy & radiopharmaceuticals.
[32] L. Heinzerling,et al. Immunologic Effector Mechanisms of a Standardized Mistletoe Extract on the Function of Human Monocytes and Lymphocytes in vitro, ex vivo, and in vivo , 2006, Journal of Clinical Immunology.
[33] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[34] K. Urech,et al. Viscotoxins, Mistletoe Lectins and their Isoforms in Mistletoe (Viscum album L.) Extracts Iscador , 2006, Arzneimittelforschung.
[35] A. Büssing,et al. Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. , 2002, Anticancer research.